Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BMO Capital Maintains Market Perform on Neurocrine Biosciences, Raises Price Target to $138

Author: Benzinga Newsdesk | May 02, 2024 10:25am
BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market Perform and raises the price target from $129 to $138.

Posted In: NBIX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist